A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study to evaluate the safety, pharmacokinetic
(PK), preliminary clinical activity, pharmacodynamic (PD), and biomarkers of AB521 as
monotherapy for advanced solid tumor malignancies (dose escalation) and clear cell renal cell
carcinoma (ccRCC) (dose expansion).